WAYNE, Pa., May 4, 2016 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that the company is scheduled to present at three upcoming conferences this Spring. Egalet will provide an update on marketed products, SPRIX® (ketorolac tromethamine) Nasal Spray and OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII, as well as and Guardian™ Technology product candidates ARYMO™ ER, an abuse-deterrent, extended release morphine, and Egalet-002, an abuse-deterrent, extended-release oxycodone. The presentations are as follows:
- Bank of America/Merrill Lynch Health Care Conference
Encore at Wynn Las Vegas, Las Vegas, NV Encore at Wynn Las Vegas, Las Vegas, NV Encore at Wynn Las Vegas, Las Vegas, NV Wednesday, May 11, 2016, 3:00 p.m.
Encore at Wynn, Las Vegas
- Jefferies 2016 Healthcare Conference
Thursday, June 9, 2016, 8:30 a.m.
Grand Hyatt, New York City
- JMP Securities Life Sciences Conference
Tuesday, June 21, 2016, 4:30 p.m.
The St. Regis, New York City
Presentations will be webcast live and available for replay at Egalet's website at http://egalet.investorroom.com/eventsandwebcasts.
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of clinical-stage, product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO™ ER, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, including the boxed warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; our ability to obtain regulatory approval of our product candidates; ability to have third parties manufacture our products; competitive factors; our ability to find and hire qualified sales professionals; general market conditions; and other risk factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/egalet-to-present-at-upcoming-investor-conferences-this-spring-300263050.html
SOURCE Egalet Corporation